| Sara Anne Davis, MD | |
|
2201 Lexington Ave, Ashland, KY 41101-2843 | |
| (606) 408-4000 | |
| (606) 408-6825 |
| Full Name | Sara Anne Davis |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 10 Years |
| Location | 2201 Lexington Ave, Ashland, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114338225 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 50531 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| King's Daughters' Medical Center | Ashland, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kings Daughters Medical Specialties Inc | 6103968029 | 328 |
News Archive
WageWorks, Inc., a leader in administering Consumer-Directed Benefits, which empower employees to save money on taxes while also providing corporate tax savings for employers, today announced the Company's financial results for its fourth quarter and fiscal year ended December 31, 2013.
In response to Michael Gerson's November 11 column in which he said the end of AIDS is possible because of combination prevention and treatment innovations, David Bryden, the Stop TB advocacy officer at RESULTS, writes in a Washington Post letter to the editor, "Another benefit of [HIV] treatment is that it sharply reduces deaths from tuberculosis [TB], which is the primary killer of people living with HIV/AIDS."
On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.
In a review published in Biotechnology Letters, the authors discuss plant-derived VLP-based vaccines.
The European Vaccine Effort against HIV/AIDS, has announced that a phase I clinical trial of novel investigational vaccines comprising DNA-HIV-C and NYVAC-HIV-C for the prevention of HIV infection has started in Lausanne and London in February 2005.
› Verified 9 days ago
| Entity Name | Kings Daughters Medical Specialties Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710215736 PECOS PAC ID: 6103968029 Enrollment ID: O20100217000538 |
News Archive
WageWorks, Inc., a leader in administering Consumer-Directed Benefits, which empower employees to save money on taxes while also providing corporate tax savings for employers, today announced the Company's financial results for its fourth quarter and fiscal year ended December 31, 2013.
In response to Michael Gerson's November 11 column in which he said the end of AIDS is possible because of combination prevention and treatment innovations, David Bryden, the Stop TB advocacy officer at RESULTS, writes in a Washington Post letter to the editor, "Another benefit of [HIV] treatment is that it sharply reduces deaths from tuberculosis [TB], which is the primary killer of people living with HIV/AIDS."
On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.
In a review published in Biotechnology Letters, the authors discuss plant-derived VLP-based vaccines.
The European Vaccine Effort against HIV/AIDS, has announced that a phase I clinical trial of novel investigational vaccines comprising DNA-HIV-C and NYVAC-HIV-C for the prevention of HIV infection has started in Lausanne and London in February 2005.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sara Anne Davis, MD Po Box 2379, Ashland, KY 41105-2379 Ph: (606) 408-6200 | Sara Anne Davis, MD 2201 Lexington Ave, Ashland, KY 41101-2843 Ph: (606) 408-4000 |
News Archive
WageWorks, Inc., a leader in administering Consumer-Directed Benefits, which empower employees to save money on taxes while also providing corporate tax savings for employers, today announced the Company's financial results for its fourth quarter and fiscal year ended December 31, 2013.
In response to Michael Gerson's November 11 column in which he said the end of AIDS is possible because of combination prevention and treatment innovations, David Bryden, the Stop TB advocacy officer at RESULTS, writes in a Washington Post letter to the editor, "Another benefit of [HIV] treatment is that it sharply reduces deaths from tuberculosis [TB], which is the primary killer of people living with HIV/AIDS."
On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.
In a review published in Biotechnology Letters, the authors discuss plant-derived VLP-based vaccines.
The European Vaccine Effort against HIV/AIDS, has announced that a phase I clinical trial of novel investigational vaccines comprising DNA-HIV-C and NYVAC-HIV-C for the prevention of HIV infection has started in Lausanne and London in February 2005.
› Verified 9 days ago
Michael Banks, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2201 Lexington Ave, Ashland, KY 41101 Phone: 606-408-4000 | |
Kayla Diann Bailey, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2201 Lexington Ave, Ashland, KY 41101 Phone: 606-408-4000 | |
Joshua Bryant, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2201 Lexington Ave, Ashland, KY 41101 Phone: 606-408-4000 | |
Emilio Punzal Jr., MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2201 Lexington Ave, Ashland, KY 41101 Phone: 606-408-4000 Fax: 606-408-6625 | |
Dr. Allen T Cochran, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2201 Lexington Ave, Ashland, KY 41101 Phone: 606-408-4000 |